Cell Therapy Treatments in Development
- ALS
FDA approves Phase II NSI-566/ALS clinical trial, expanding trial to two centers with significant increase in dosing, in April 2013. Phase II trial expected to commence in the second half of 2013. In Mexico City, ALS Phase I / II trial expected to commence in the second half of 2013. More
- Ischemic Stroke
Phase I / II trial for ischemic stroke expected to be underway in the second quarter of 2013 in collaboration with BaYi Brain Hospital in Beijing. More
- Spinal Cord Injury
FDA approved Phase I safety trial transplanting NSI-566 into the T2-T12 lumbar regions of chronic SCI patients, in January 2013. Phase I commencement expected in the third quarter of 2013. Acute SCI trial expected to commence in Seoul, South Korea in the second half of 2013. More
- Glioblastoma (Brain Cancer)
Preclinical phase in collaboration with Loma Linda University as part of a U.S. Department of Defense-funded research program, entitled “Research to Treat Cancerous Brain Tumors with Neural Stem Cells.”
- Multiple Sclerosis
Preclinical phase with NSI-566. Further clinical development on multiple sclerosis application pending NSI-566 ALS ongoing trial.
- Optic Neuritis
Preclinical phase with NSI-566. Further clinical development on optic neuritis application pending NSI-566 ALS ongoing trial.
- Alzheimer’s Disease
Preclinical phase with NSI-566. Further clinical development on Alzheimer’s disease application pending NSI-566 ALS ongoing trial.
- Traumatic Brain Injury
Preclinical phase with NSI-566. Further clinical development on traumatic brain injury application pending NSI-566 ALS ongoing trial.
- Peripheral Nerve Injury
Preclinical phase with NSI-566. Further clinical development on peripheral nerve injury application pending NSI-566 ALS ongoing trial.
- Diabetic Neuropathy
Preclinical phase with NSI-566. Further clinical development on diabetic neuropathy application pending NSI-566 ALS ongoing trial.
- Lysosomal Diseases
Preclinical phase with NSI-566. Further clinical development on lysosomal diseases application pending NSI-566 ALS ongoing trial.
- Parkinson’s Disease
Preclinical phase with NSI-566. Further clinical development on Parkinson’s disease application pending NSI-566 ALS ongoing trial.
- Huntington’s Disease
Preclinical phase with NSI-566. Further clinical development on Huntington’s disease application pending NSI-566 ALS ongoing trial.
- Cerebral Palsy
Preclinical phase with NSI-566. Further clinical development on cerebral palsy application pending NSI-566 ALS ongoing trial.
- Ischemic Spastic Paraplegia
Preclinical phase with the University of California at San Diego. Lead collaborator, Dr. Martin Marsala, PhD authored a peer-reviewed paper on study results. More
Drug Treatments in Development
- Major Depressive Disorder
Phase Ib trial for neurogenic small molecule drug, NSI-189 advances to third and final cohort in April 2013, testing safety and tolerability of escalating doses of NSI-189 for 28 daily administrations. Phase Ib trial expected to be completed in 3Q13. More
- Alzheimer’s Disease
Preclinical phase with NSI-189, which was originally developed to address cognitive indications. Further clinical development on Alzheimer’s disease application pending NSI-189 major depressive disorder ongoing trial.
- Cognitive complication due to Diabetes
Preclinical phase with NSI-189. Further clinical development on cognitive complication due to diabetes application pending NSI-189 major depressive disorder ongoing trial.
- Stroke
Preclinical phase with NSI-189. Further clinical development on stroke application pending NSI-189 major depressive disorder ongoing trial.
- Traumatic Brain Injury
Preclinical phase with NSI-189. Further clinical development on traumatic brain injury application pending NSI-189 major depressive disorder ongoing trial.
- Post-Traumatic Stress Disorder
Preclinical phase with NSI-189. Further clinical development on PTSD application pending NSI-189 major depressive disorder ongoing trial.
- Neurodegeneration
Preclinical phase with NSI-189. Further clinical development on neurodegeneration application pending NSI-189 major depressive disorder ongoing trial.
- Anti-Aging (Nootropic)
Preclinical phase with NSI-189. Further clinical development on anti-aging (nootropic) application pending NSI-189 major depressive disorder ongoing trial.
